Mostrar el registro sencillo del ítem
Cell-based therapies for COVID-19: A living, systematic review
dc.contributor.author | Rada, Gabriel et al. | |
dc.date.accessioned | 2021-04-01T20:04:10Z | |
dc.date.available | 2021-04-01T20:04:10Z | |
dc.date.issued | 2020-12-17 | |
dc.identifier.uri | http://doi.org/10.5867/medwave.2020.11.8078 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12663/2566 | |
dc.description.abstract | Objective: This living, systematic review aims to provide a timely, rigorous, and continuously updated summary of the available evidence on the role of cell-based therapies in the treatment of patients with COVID-19. Data sources: We conducted searches in PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), grey literature, and in a centralized repository in L·OVE (Living OVerview of Evidence). L·OVE is a platform that maps PICO questions to evidence from the Epistemonikos database. In response to the COVID-19 emergency, L·OVE was adapted to expand the range of evidence it covers and customized to group all COVID-19 evidence in one place. All the searches covered the period until 23 April 2020 (one day before submission). Eligibility criteria for selecting studies and methods: We adapted an already published standard protocol for multiple parallel systematic reviews to the specificities of this question. We searched for randomized trials evaluating the effectiveness and safety of cell-based therapies versus placebo or no treatment in patients with COVID-19. Anticipating the lack of randomized trials directly addressing this question, we also searched for trials evaluating other coronavirus infections, such as MERS-CoV and SARS-CoV, and nonrandomized studies in COVID-19. Two reviewers independently screened each study for eligibility. A living, web-based version of this review will be openly available during the COVID-19 pandemic. We will resubmit this review to a peer-reviewed journal every time the conclusions change or whenever there are substantial updates. Results: We screened 1 043 records, but no study was considered eligible. We identified 61 ongoing studies, including 39 randomized trials evaluating different types of cell-based therapies in COVID-19. Conclusions: We did not find any studies that met our inclusion criteria, and hence there is no evidence to support or refute the use of cell-based therapies for treating patients with COVID-19. A substantial number of ongoing studies should provide valuable evidence to inform researchers and decision-makers in the near future. | en_US |
dc.language | English | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Coronavirus Infections | en_US |
dc.subject | Infectious Diseases | en_US |
dc.subject | Coronavirus | en_US |
dc.subject | Betacoronavirus | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.subject | Systematic Review | en_US |
dc.subject | Mesenchymal Stem Cells | en_US |
dc.subject | Cell- and Tissue-Based Therapy | en_US |
dc.title | Cell-based therapies for COVID-19: A living, systematic review | en_US |
eihealth.country | Others | en_US |
eihealth.category | Candidate therapeutics RD | en_US |
eihealth.type | Published Article | en_US |
eihealth.maincategory | Save Lives / Salvar Vidas | en_US |
dc.relation.ispartofjournal | Medwave | en_US |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |